High-flow nasal cannula therapy for infants with bronchiolitis

Area of Science:

• Pediatrics
• Respiratory Medicine
• Critical Care

Background:

• Bronchiolitis is a common viral illness in infants, causing airway obstruction and respiratory distress.
• Current treatments are primarily supportive, lacking effective pharmacotherapy.
• Heated, humidified, high-flow nasal cannula (HFNC) therapy offers an alternative to conventional respiratory support.

Purpose of the Study:

• To evaluate the effectiveness of HFNC compared to conventional respiratory support for infants with bronchiolitis.

Main Methods:

• Searched multiple databases for randomized controlled trials (RCTs) and quasi-RCTs.
• Included studies comparing HFNC (flow rates > 4 L/min) with conventional treatment in infants (< 24 months) diagnosed with bronchiolitis.
• Extracted data on study characteristics, risk of bias, and outcomes including need for invasive support and length of stay.

Main Results:

• One small pilot RCT (19 participants) was included, comparing HFNC to oxygen via head box.
• HFNC group showed higher oxygen saturation at 8 and 12 hours, but no significant difference in duration of oxygen therapy, discharge time, or length of stay.
• No adverse events were reported; no participants required further respiratory support.

Conclusions:

• Insufficient evidence exists to confirm HFNC effectiveness for infant bronchiolitis due to low-quality evidence from one small study.
• HFNC appears feasible and well-tolerated, but further research is necessary.
• Ongoing trials are expected to provide more data for future reviews.